Abstract 2751
Background
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal (GI) tract. The size, the presence of a c-KIT gene mutation and the mitotic index are used to determine the prognosis and to direct systemic treatment choices. This study evaluated the use of radiomics, a technique which uses algorithms for diagnosing and predicting the c-KIT mutational status and mitotic index of GISTs from medical imaging features.
Methods
A combination of machine learning methods was used to distinguish treatment-naive GISTs from other GI tumors resembling GISTs on imaging, based on clinical and molecular characteristics, as well as imaging features extracted from the contrast-enhanced venous phase computed tomography scans. Evaluation was performed in a 100x random-split cross-validation with 20% of the data for testing.
Results
A total of 242 tumors were used for distinguishing GISTs (n = 123) from non-GISTs (n = 119) including leiomyoma (n = 25), schwannoma (n = 21), gastric carcinoma (n = 25), lymphoma (n = 23) and leiomyosarcoma (n = 25).The non-GISTs were located either gastric (23%) or non-gastric (77%) and the GISTs were located either gastric (63%) or non-gastric (37%). A c-KIT mutation was present in the majority of the GISTs (exon 9 n = 10, exon 11 n = 56, exon 13 n = 2). The dataset originated from 65 different scanners, leading to heterogeneity in the imaging protocols. Imaging feature analyses showed a mean area under the curve (mAUC) of 0.70 (95% confidence interval [CI] 0.63-0.76) for distinguishing GIST from non-GISTs. A mAUC of 0.52 (95% CI 0.32-0.72) was found for predicting all c-KIT mutations, a mAUC of 0.51 (95% CI 0.29-0.72) for predicting a c-KIT exon 9 mutation, and a mAUC of 0.61 (95% CI 0.47-0.74) for predicting a c-KIT exon 11 mutation. The mitotic index was available in 83 patients (≤5/50 high power fields (HPFs) n = 53, 43.1%, >5/50 HPFs n = 33, 26.8%), and showed a mAUC of 0.60 (95% CI 0.47-0.73).
Conclusions
This pilot study showed the potential of radiomics to distinguish GIST from other GI tumors, but no potential in predicting c-KIT mutational status and mitotic index of GISTs. Further optimization and validation of the radiomics model is required to incorporate radiomics in the diagnostic routine of GISTs.
Clinical trial identification
Editorial acknowledgement
M.J. Timbergen and M.P.A. Starmans contributed equally to this study.
Legal entity responsible for the study
The authors.
Funding
The Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract